Review of the efficacy of AST-120 (KREMEZIN®) on renal function in chronic kidney disease patients

AST-120 (KREMEZIN®) consists of oral, spherical carbon particles that adsorb uremic toxins and their precursors within the gastrointestinal tract, allowing them to be excreted in the feces. Uremic toxins such as indoxyl sulfate and p-cresyl sulfate are abundant in the blood of chronic kidney disease...

Full description

Bibliographic Details
Main Authors: Mayumi Asai, Sei Kumakura, Mami Kikuchi
Format: Article
Language:English
Published: Taylor & Francis Group 2019-01-01
Series:Renal Failure
Subjects:
ckd
Online Access:http://dx.doi.org/10.1080/0886022X.2018.1561376
id doaj-2937b596faca4e9ab1fd48f8c0d5e5d3
record_format Article
spelling doaj-2937b596faca4e9ab1fd48f8c0d5e5d32021-06-02T08:05:28ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492019-01-01411475610.1080/0886022X.2018.15613761561376Review of the efficacy of AST-120 (KREMEZIN®) on renal function in chronic kidney disease patientsMayumi Asai0Sei Kumakura1Mami Kikuchi2Kureha CorporationKureha CorporationKureha CorporationAST-120 (KREMEZIN®) consists of oral, spherical carbon particles that adsorb uremic toxins and their precursors within the gastrointestinal tract, allowing them to be excreted in the feces. Uremic toxins such as indoxyl sulfate and p-cresyl sulfate are abundant in the blood of chronic kidney disease (CKD) patients and are related to the progression of both CKD and cardiovascular disease. AST-120 was approved in Japan in 1991 followed by Korea (2004), Taiwan (2007) and the Philippines (2010) for treating uremic symptoms and prolonging the time to initiation of dialysis in patients with progressive CKD. In this review, we provide an overview of the past clinical data on AST-120 from 1982 to 2013. The effect of AST-120 for renal events was not supported in the primary analysis of randomized clinical trials. However, post-hoc analyses revealed significant differences between the AST-120 and control groups in the second Japanese phase III trial and in the multinational Evaluating Prevention of Progression in CKD (EPPIC) trials. Furthermore, inhibitory effects on the progression of CKD, as represented by amelioration in the estimated glomerular filtration rate (eGFR) decline and serum creatinine (sCr) elevation were suggested. These results suggest that AST-120 delays the decline in renal function. In addition, AST-120 may prolong the time to the initiation of dialysis, especially in patients with progressive CKD. For further verification of the clinical efficacy of AST-120, future study inclusion criteria should be determined carefully, defining progressive CKD using markers such as declines in eGFR and sCr elevation.http://dx.doi.org/10.1080/0886022X.2018.1561376ast-120ckdclinical trialspherical carbon adsorbenturemic toxin
collection DOAJ
language English
format Article
sources DOAJ
author Mayumi Asai
Sei Kumakura
Mami Kikuchi
spellingShingle Mayumi Asai
Sei Kumakura
Mami Kikuchi
Review of the efficacy of AST-120 (KREMEZIN®) on renal function in chronic kidney disease patients
Renal Failure
ast-120
ckd
clinical trial
spherical carbon adsorbent
uremic toxin
author_facet Mayumi Asai
Sei Kumakura
Mami Kikuchi
author_sort Mayumi Asai
title Review of the efficacy of AST-120 (KREMEZIN®) on renal function in chronic kidney disease patients
title_short Review of the efficacy of AST-120 (KREMEZIN®) on renal function in chronic kidney disease patients
title_full Review of the efficacy of AST-120 (KREMEZIN®) on renal function in chronic kidney disease patients
title_fullStr Review of the efficacy of AST-120 (KREMEZIN®) on renal function in chronic kidney disease patients
title_full_unstemmed Review of the efficacy of AST-120 (KREMEZIN®) on renal function in chronic kidney disease patients
title_sort review of the efficacy of ast-120 (kremezin®) on renal function in chronic kidney disease patients
publisher Taylor & Francis Group
series Renal Failure
issn 0886-022X
1525-6049
publishDate 2019-01-01
description AST-120 (KREMEZIN®) consists of oral, spherical carbon particles that adsorb uremic toxins and their precursors within the gastrointestinal tract, allowing them to be excreted in the feces. Uremic toxins such as indoxyl sulfate and p-cresyl sulfate are abundant in the blood of chronic kidney disease (CKD) patients and are related to the progression of both CKD and cardiovascular disease. AST-120 was approved in Japan in 1991 followed by Korea (2004), Taiwan (2007) and the Philippines (2010) for treating uremic symptoms and prolonging the time to initiation of dialysis in patients with progressive CKD. In this review, we provide an overview of the past clinical data on AST-120 from 1982 to 2013. The effect of AST-120 for renal events was not supported in the primary analysis of randomized clinical trials. However, post-hoc analyses revealed significant differences between the AST-120 and control groups in the second Japanese phase III trial and in the multinational Evaluating Prevention of Progression in CKD (EPPIC) trials. Furthermore, inhibitory effects on the progression of CKD, as represented by amelioration in the estimated glomerular filtration rate (eGFR) decline and serum creatinine (sCr) elevation were suggested. These results suggest that AST-120 delays the decline in renal function. In addition, AST-120 may prolong the time to the initiation of dialysis, especially in patients with progressive CKD. For further verification of the clinical efficacy of AST-120, future study inclusion criteria should be determined carefully, defining progressive CKD using markers such as declines in eGFR and sCr elevation.
topic ast-120
ckd
clinical trial
spherical carbon adsorbent
uremic toxin
url http://dx.doi.org/10.1080/0886022X.2018.1561376
work_keys_str_mv AT mayumiasai reviewoftheefficacyofast120kremezinonrenalfunctioninchronickidneydiseasepatients
AT seikumakura reviewoftheefficacyofast120kremezinonrenalfunctioninchronickidneydiseasepatients
AT mamikikuchi reviewoftheefficacyofast120kremezinonrenalfunctioninchronickidneydiseasepatients
_version_ 1721406675871596544